The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Renal sarcoidosis treatment is based on steroids, but the dose and duration are unknown. Despite this treatment, most patients will have chronic kidney disease. From our previous studies, the investigators believe that high dose steroids by methylprednisolone bolus will improve patient outcome and renal function.

Condition or disease

Intervention/treatment

Phase

Renal Sarcoidosis

Drug: methylprednisolone bolus IV 15 mg/kg/d for 3 days.

Not Applicable

Detailed Description:

In a multicentric, randomized, open trial, the investigators will assess the efficacy of methylprednisolone bolus at 15mg/kg/d for 3 days before oral steroids on renal function improvement in renal sarcoidosis patients.

Percentage of patients with a positive response defined by eGRF better than 100% compared to eGRF prior treatment or a normalization of renal function. [ Time Frame: 3 months after the beginning of the treatment ]

Secondary Outcome Measures :

Efficacy (eGFR, percentage of patients with a eGRF < 60 ml/min/1.73m²) [ Time Frame: 1, 3, 6 and 12 months after the beginning of the treatment ]

Extra-renal manifestations [ Time Frame: 1, 3, 6 and 12 months after the beginning of the treatment ]

incidence of arrhythmias and cardiac conduction disease [ Time Frame: 1, 3, 6 and 12 months after the beginning of the treatment ]

fragility fracture [ Time Frame: 1, 3, 6 and 12 months after the beginning of the treatment ]

neuro-psychiatric troubles and infections [ Time Frame: 1, 3, 6 and 12 months after the beginning of the treatment ]

number of renal and extra-renal relapses. [ Time Frame: 1, 3, 6 and 12 months after the beginning of the treatment ]

Characterization of vitamin and calcium deficiencies by blood and urinary dosages [ Time Frame: 1, 3, 6 and 12 months after the beginning of the treatment ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Acute renal failure from other causes. If hypercalcaemia is greater than 3 mmol/L, the correction of any dehydration will systematically salt intake, followed of renal function control before inclusion.